Vusolimogene oderparepvec-wtpg

Brand names: Tudriqev · Active ingredient: Vusolimogene Oderparepvec

In short: TUDRIQEV™ is indicated in combination with nivolumab for the treatment of adult patients with unresectable advanced cutaneous melanoma who experienced disease progression with a programmed death receptor-1 (PD-1)-blocking antibody-based regimen. This indication is approved under accelerated approval

Forms & strengthsTUDRIQEV is a colorless, translucent to opaque suspension provided as a 1 mL extractable volume in a single-dose vial in the following concentrations: Starting dose: 106 (1 million) PFU per mL suspension (white cap) Subsequent doses: 107 (10 million) PFU per …
LabelReplimune, Inc.
Label updatedSep 17, 2026

What is Vusolimogene oderparepvec-wtpg used for?

TUDRIQEV™ is indicated in combination with nivolumab for the treatment of adult patients with unresectable advanced cutaneous melanoma who experienced disease progression with a programmed death receptor-1 (PD-1)-blocking antibody-based regimen.

This indication is approved under accelerated approval based on objective response rate (ORR) and duration of response . Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s).

Vusolimogene oderparepvec-wtpg dosage

For intratumor injection only. DO NOT administer intravenously.

The recommended dosage of TUDRIQEV is 1 mL/cm of the largest dimension of the tumor for a maximum of 10 mL across all lesions treated with each dose.

Administer intratumor injections of TUDRIQEV every two weeks for 8 consecutive doses starting at a concentration of 106 plaque-forming units (PFU) per mL at Week 1 followed by 107 PFU per mL for subsequent weeks.

Assess the size of each injectable lesion on each treatment day to determine the required TUDRIQEV volume.

If multiple tumors are present, prioritize the most rapidly growing and largest new or existing lesions suitable for injection.

Patients with no confirmed disease progression could be retreated with TUDRIQEV at a concentration of 107 PFU/mL every two weeks.

Administer nivolumab as intravenous injection starting at Week 3. Refer to the nivolumab prescribing information for the dosage and administration information including dose modifications, preparation, and administration .

Avoid accidental exposure to TUDRIQEV by wearing appropriate personal protective equipment (PPE). Observe standard precautions when preparing and administering TUDRIQEV .

Clean surfaces that may have come in contact with TUDRIQEV (including spills) with broad spectrum virucidal agent such as 70% isopropanol alcohol or 1% sodium hypochlorite.

Dispose of the used vials and all materials that may have come in contact with TUDRIQEV as biohazardous waste.

TUDRIQEV should be prepared by a healthcare professional experienced in the use of anticancer therapy.

Determine the volume required for injection .

Thaw TUDRIQEV vials inside the original carton at room temperature [15°C to 25°C (59°F to 77°F)] or during refrigeration [2°C to 8°C (36° to 46°F)]. DO NOT refreeze TUDRIQEV after thawing .

Swirl gently, inspect vial. Particles may be visible . If settlement occurs, re-suspend by gently swirling. DO NOT shake.

Using aseptic technique, withdraw the required TUDRIQEV dosage volume from the vial(s) into the syringe(s) to be used for administration.

Select needles gauged between 17G and 27G based on the location and characteristics of the tumors to be injected. A higher needle gauge will allow for a smaller puncture in tissue and will reduce leakage of TUDRIQEV along the needle tract. A lower needle gauge is needed for fibrotic or deeper lesions.

Administer TUDRIQEV within 2 hours of syringe preparation .

DO NOT administer TUDRIQEV into brain or spinal cord tumors or scalp tumors with moderate to extensive bone erosion. Avoid tumors that encase, invade, or occlude major blood vessels, major nerve structures, or airways. Avoid direct injection into blood vessels.

Pre-Injection

Clean the skin areas where the needle will be inserted with an alcohol swab and let dry. …

How to take Vusolimogene oderparepvec-wtpg — instructions & advice from the label

Discuss following with patients and/or caregivers.

Accidental exposure to TUDRIQEV: Inform patients and/or caregivers that accidental exposure of TUDRIQEV to close contacts and caregivers may lead to transmission of herpetic infection. To prevent the risk of accidental exposure and viral transmission, instruct patients, caregiver, and close contacts on following.

Avoid unprotected direct contact with injection sites, dressing, and bodily fluid of patients.

Avoid touching or scratching the injection sites.

Wash hands thoroughly in case of direct contact and prior to and after changing the dressing.

Keep the injection site(s) covered with the dressing for at least 48 hours. Replace the dressing if it falls off. Wear gloves when removing and replacing the dressing.

Place used dressing, gloves, and cleaning materials in sealed plastic bags prior to disposal in household waste.

If an accidental exposure to TUDRIQEV occurs (e.g. touching or scratching the unprotected injection site or dressings), exposed individuals should clean the affected area with soap and water. …

Warnings & precautions

Do not take this medicine if: None.

Accidental exposure of TUDRIQEV to close contacts may lead to transmission of herpetic infection. Healthcare providers, caregivers, close contacts, pregnant women, newborns, and patients should avoid direct contact with injected tumors, dressings, or bodily fluids of patients .

Healthcare providers and caregivers must wear protective gloves when applying or changing dressings and dispose of used dressings, gloves, and cleaning materials as biohazardous waste .

If an accidental exposure to TUDRIQEV occurs (e.g. touching or scratching the unprotected injection site or dressings), exposed individuals should clean the affected area with soap and water. If signs and symptoms of herpetic infection develop, exposed individuals should contact their healthcare provider for assessment and treatment as clinically warranted.

There is a potential risk for herpetic infection or reactivation after TUDRIQEV administration. Patients with suspected herpetic infections should contact their healthcare provider for assessment and antiviral treatment of the suspected herpetic infection as clinically warranted.

Complications related to injection procedure have occurred, including but not limited to hemorrhage, infection, and visceral injury (for example: pneumothorax). . Monitor patients for signs and symptoms of visceral injury during and after TUDRIQEV administration and manage according to clinical practice.

TUDRIQEV in combination with nivolumab may result in immune-mediated events. In clinical studies, immune-mediated events, including colitis, hepatitis, myocarditis, neuropathy, capillary leak syndrome, dermatitis, and vitiligo have been reported in patients treated with TUDRIQEV and nivolumab .

Vusolimogene oderparepvec-wtpg side effects

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The safety data described in this section reflect exposure of TUDRIQEV administered with nivolumab in 140 patients evaluated in the IGNYTE Study .

Patients received a median of 8 doses (range 1 to 32) of TUDRIQEV, and 7 (range 0 to 29) doses of nivolumab during the study. The median duration of the first course of TUDRIQEV and nivolumab exposure was 3.3 months (range 0.5 to 5.1 months) and 3.2 months (range 0 to 24.4 months), respectively.

Serious adverse reactions occurring in >1% patients include pleural effusion (n=3), acute kidney injury (n=2), arthralgia (n=2), atrial fibrillation (n=2), atrial flutter (n=2), cancer pain (n=2), hypophysitis (n=2), immune-mediated enterocolitis (n=2), pyrexia (n=2), sepsis (n=2), urinary tract infection (n=2), and myocardial infarction (n=2). Serious adverse reactions leading to death include myocardial infarction (n=1) and multiple organ dysfunction (n=1). Adverse reactions leading to discontinuation of treatment occurred in 22 (16%) patients.

Table 1 summarizes the most common adverse reactions that occurred in ≥10% patients in the IGNYTE Study.

Adverse ReactionsGraded per National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. …

Drug interactions

Antiviral medications may reduce the efficacy of TUDRIQEV. Patients receiving systemic antiviral treatment for herpetic infection should delay TUDRIQEV treatment for 72 hours after completion of antiviral therapy.

About this medicine

TUDRIQEV (vusolimogene oderparepvec-wtpg) is a genetically modified herpes simplex virus, type 1 (HSV-1) oncolytic viral therapy that encodes a fusogenic glycoprotein derived from gibbon ape leukemia virus with the R sequence deleted (GALV-GP-R–) and human granulocyte-macrophage colony-stimulating factor (GM-CSF). The genes encoding the HSV-1 neurovirulence factor ICP34.5 and the transporter associated with antigen presentation inhibitor ICP47 are deleted from TUDRIQEV.

TUDRIQEV is a sterile frozen, preservative free, suspension for intratumor injection provided in single-dose glass vials. Each vial contains an extractable volume of 1 mL of TUDRIQEV at a concentration of either 106 PFU/mL or 107 PFU/mL formulated in disodium hydrogen phosphate dihydrate (7 mg), sodium dihydrogen phosphate dihydrate (1.4 mg), sodium chloride (1.3 mg), myo-inositol (39 mg), d-sorbitol (19.5 mg), recombinant human serum albumin (5.1 mg) with water for injection. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 26627b8d-91ac-4f76-a213-7e25efd024d1. Read the full official label on DailyMed.

Related medicines

Levothyroxine Allopurinol Ondansetron Finasteride Clonidine Testosterone Thyroid Methotrexate